Axios @axios
The FDA acting commissioner has called for an independent review of Alzheimer’s drug Aduhelm, a rare move from the agency after reports detailed how manufacturer Biogen possibly violated FDA rules with an "off-the-books" meeting with agency officials. https://t.co/HYzsEmJ5u1 — PolitiTweet.org
